Novo Nordisk says real-world study finds Ozempic 2 mg vs Mounjaro lowers major CV risk by 6%
Novo Nordisk said a real-world study of 636,525 adults with type 2 diabetes found escalated-dose Ozempic 2 mg had a statistically significant 6% lower risk of major adverse cardiovascular events versus switching to Mounjaro doses up to 15 mg, with results presented at the EASD meeting in Milan.
(Adds trial details and background in paragraphs 2 to 8) COPENHAGEN, Sept 29 (Reuters) — Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's Mounjaro. The company said patients who escalated their dose of Ozempic to 2 milligrams (mg) from 1 mg saw a statistically significant 6% lower risk of major adverse cardiovascular events compared to those who switched to Mounjaro doses of up to 15 mg.
The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan, Italy. 2% increased to Ozempic 2 mg or switched to Mounjaro. 7% had switched to Mounjaro. "These real-world findings can help provide insights into how intensification strategies may affect cardiovascular outcomes as an important factor in patient care," said Michael Radin, executive medical director at Novo.
The findings build upon an earlier analysis of these data, which examined HbA1c, a measure of blood-glucose levels over time, and weight loss. Novo and Lilly are locked in a fierce battle for dominance in the US obesity drug market, which analysts expect to reach between $100 billion and $150 billion by 2030. com; +45 21 27 97 79;)